In patients with metastatic colorectal cancer harboring a BRAF V600E mutation, the combo not only staved off disease progression but it also significantly extended patients’ lives compared with ...
"The BRAFTOVI regimen is emerging as a new standard of care as the first targeted therapy approved for use as early as first-line for patients with mCRC with a BRAF V600E mutation. We look forward ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback